KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Neogenomics (NEO) over the last 17 years, with Q4 2025 value amounting to $5.9 million.

  • Neogenomics' Gains from Investment Securities rose 189295.3% to $5.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $6.4 million, marking a year-over-year increase of 93679.09%. This contributed to the annual value of $6.4 million for FY2025, which is 93679.09% up from last year.
  • As of Q4 2025, Neogenomics' Gains from Investment Securities stood at $5.9 million, which was up 189295.3% from $458000.0 recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Gains from Investment Securities ranged from a high of $7.3 million in Q4 2023 and a low of -$49000.0 during Q1 2021
  • For the 5-year period, Neogenomics' Gains from Investment Securities averaged around $990800.0, with its median value being $129000.0 (2022).
  • As far as peak fluctuations go, Neogenomics' Gains from Investment Securities crashed by 255000.0% in 2021, and later surged by 2928000.0% in 2023.
  • Over the past 5 years, Neogenomics' Gains from Investment Securities (Quarter) stood at $35000.0 in 2021, then fell by 28.57% to $25000.0 in 2022, then surged by 29280.0% to $7.3 million in 2023, then crashed by 95.94% to $298000.0 in 2024, then skyrocketed by 1892.95% to $5.9 million in 2025.
  • Its Gains from Investment Securities stands at $5.9 million for Q4 2025, versus $458000.0 for Q2 2025 and $298000.0 for Q4 2024.